Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

吉非替尼治疗化疗失败的晚期非小细胞肺癌疗效观察

Jia Xuefeng,Liu Ning,Zhang Bin

Journal of Basic and Clinical Oncology（2013）

Cited 0|Views8
No score
Abstract
目的观察吉非替尼治疗化疗失败的晚期非小细胞肺癌(NSCLC)的疗效及毒副反应。方法对32例化疗失败的晚期NSCLC患者给予吉非替尼250 mg,口服,每天1次,至病情进展或出现不可耐受的毒副反应。结果 32例患者中,CR 0例(0.00%),PR 8例(25.00%),SD 13例(40.62%),PD 11例(34.38%),有效率为25.00%,疾病控制率为65.62%,中位疾病进展时间为5.2个月,中位生存时间为9.3个月,1 a生存率为34.38%。结论吉非替尼治疗晚期NSCLC有较好的疗效,毒副反应可耐受。
More
Translated text
Key words
non-small cell lung cancer,gefitinib,chemotherapy
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined